China guideline for the screening and early detection of female breast cancer(2021, Beijing)
10.3760/cma.j.cn112152-20210119-00061
- VernacularTitle:中国女性乳腺癌筛查与早诊早治指南(2021，北京)
- Author:
Jie HE
1
;
Wanqing CHEN
;
Ni LI
;
Hongbing SHEN
;
Jiang LI
;
Yong WANG
;
Jing LI
;
Jinhui TIAN
;
Baosen ZHOU
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院 100021
- Keywords:
Breast neoplasms;
Female;
Screening;
Early diagnosis and treatment;
Guideline;
China
- From:
Chinese Journal of Oncology
2021;43(4):357-382
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is the commonest malignant tumor among Chinese females, ranking first in terms of incidence of female cancers. Commissioned by the Disease Prevention and Control Bureau of National Health Commission of the People′s Republic of China, the National Cancer Center formulated the Guideline for Screening and Early Diagnosis and Treatment of Female Breast Cancer in China according to WHO Handbook for Guideline Development. The methods on Cochrane China were referred to for the formulation of the system evaluation procedures. The GRADE methods for assessment, formulation and evaluation were adopted for the classification of evidence quality and recommendation strength, and the items were reported according to Reporting Items for Practice Guidelines in Healthcare. Based on the results of evaluation, the guideline gives evidence-based recommendations for the appropriate population and technical procedures for breast cancer screening and early diagnosis and treatment after comprehensive consideration of China′s national conditions, the advantages and disadvantages of the evidence, the quality of the evidence, the economic cost of screening, the feedback of multidisciplinary clinical research respondents, and in-person expert consensus. It is aimed at regulating the practices of female breast cancer screening and early diagnosis and treatment and enhancing the effectiveness of the prevention and control of female breast cancer in China.
